NCT04502368

Brief Summary

Fiberoptic bronchoscopy (FOB) is widely used as a diagnostic or therapeutic procedure in intensive care units. Patients with ARDS or COVID-19 disease often undergoes to these procedures. However, intensive care patients might suffer from serious side effects such as prolonged oxygen desaturation and adverse change in lung compliance and resistance. This study aims to evaluate these changes and determine their impact on patient stability.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
15

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Sep 2020

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 3, 2020

Completed
3 days until next milestone

First Posted

Study publicly available on registry

August 6, 2020

Completed
26 days until next milestone

Study Start

First participant enrolled

September 1, 2020

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 30, 2021

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

April 30, 2021

Completed
Last Updated

February 8, 2021

Status Verified

February 1, 2021

Enrollment Period

7 months

First QC Date

August 3, 2020

Last Update Submit

February 5, 2021

Conditions

Keywords

Respiratory InsufficiencyRespiratory Distress SyndromeMechanical VentilationCOVID-19Fiberoptic Bronchoscopy (FOB)Bronchoalveolar Lavage (BAL)

Outcome Measures

Primary Outcomes (1)

  • Regional Compliance Variation

    The variation of regional compliance, calculated by electrical impedance

    From FOB/BAL to 6 hours later

Secondary Outcomes (8)

  • Regional Resistance Variation

    From FOB/BAL to 6 hours later

  • Regional Compliance and FOB duration

    From FOB/BAL to 6 hours later

  • Regional Compliance and PaO2

    From FOB/BAL to 6 hours later

  • Atelectasis areas and BAL flooded areas

    From FOB/BAL to 6 hours later

  • PaO2 and PaO2/FiO2 ratio

    From FOB/BAL to 6 hours later

  • +3 more secondary outcomes

Interventions

FOB under full sedation (RASS sedation scale -5) and full paralysis.

BAL under full sedation (RASS sedation scale -5) and full paralysis. Lavage: NaCl 0,9% 50ml x 3 in lung region targetted according to RX/CT scan.

Realtime thoracic impedance coupled with ventilation parameters recording.

Also known as: PulmoVista® 500 - Draeger

Multiples Arterial Blood Gas test (ABG) via arterial catheter.

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Intensive Care Unit admitted patients

You may qualify if:

  • Mechanically ventilated ICU patients requiring a FOB or FOB + BAL

You may not qualify if:

  • PaO2/FiO2 ratio \<100
  • Age \< 18 years
  • Pregnancy
  • Unstable angina and recent (less than 1 week) myocardial infarction
  • Uncontrolled cranial hypertension
  • Major hemodynamic instability
  • Any previous lung surgery (except for lung transplantation)
  • Obesity (BMI \> 50)
  • Chest circumference \> 150 cm
  • Electronic implanted device (pacemaker, neurostimulator, etc.)
  • Patients who had undergone several bronchoscopy procedures could not be included twice.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Erasme University Hospital - Intensive Care Unit

Brussels, 1070, Belgium

RECRUITING

Related Publications (6)

  • Du Rand IA, Blaikley J, Booton R, Chaudhuri N, Gupta V, Khalid S, Mandal S, Martin J, Mills J, Navani N, Rahman NM, Wrightson JM, Munavvar M; British Thoracic Society Bronchoscopy Guideline Group. British Thoracic Society guideline for diagnostic flexible bronchoscopy in adults: accredited by NICE. Thorax. 2013 Aug;68 Suppl 1:i1-i44. doi: 10.1136/thoraxjnl-2013-203618. No abstract available.

    PMID: 23860341BACKGROUND
  • Kamel T, Helms J, Janssen-Langenstein R, Kouatchet A, Guillon A, Bourenne J, Contou D, Guervilly C, Coudroy R, Hoppe MA, Lascarrou JB, Quenot JP, Colin G, Meng P, Roustan J, Cracco C, Nay MA, Boulain T; Clinical Research in Intensive Care Sepsis Group (CRICS-TRIGGERSEP). Benefit-to-risk balance of bronchoalveolar lavage in the critically ill. A prospective, multicenter cohort study. Intensive Care Med. 2020 Mar;46(3):463-474. doi: 10.1007/s00134-019-05896-4. Epub 2020 Jan 7.

    PMID: 31912201BACKGROUND
  • Bauer TT, Torres A, Ewig S, Hernandez C, Sanchez-Nieto JM, Xaubet A, Agusti C, Rodriguez-Roisin R. Effects of bronchoalveolar lavage volume on arterial oxygenation in mechanically ventilated patients with pneumonia. Intensive Care Med. 2001 Feb;27(2):384-93. doi: 10.1007/s001340000781.

    PMID: 11396283BACKGROUND
  • Trouillet JL, Guiguet M, Gibert C, Fagon JY, Dreyfuss D, Blanchet F, Chastre J. Fiberoptic bronchoscopy in ventilated patients. Evaluation of cardiopulmonary risk under midazolam sedation. Chest. 1990 Apr;97(4):927-33. doi: 10.1378/chest.97.4.927.

    PMID: 2108848BACKGROUND
  • Klein U, Karzai W, Zimmermann P, Hannemann U, Koschel U, Brunner JX, Remde H. Changes in pulmonary mechanics after fiberoptic bronchoalveolar lavage in mechanically ventilated patients. Intensive Care Med. 1998 Dec;24(12):1289-93. doi: 10.1007/s001340050764.

    PMID: 9885882BACKGROUND
  • Costa EL, Borges JB, Melo A, Suarez-Sipmann F, Toufen C Jr, Bohm SH, Amato MB. Bedside estimation of recruitable alveolar collapse and hyperdistension by electrical impedance tomography. Intensive Care Med. 2009 Jun;35(6):1132-7. doi: 10.1007/s00134-009-1447-y. Epub 2009 Mar 3.

    PMID: 19255741BACKGROUND

MeSH Terms

Conditions

Respiration DisordersRespiratory InsufficiencyRespiratory Distress SyndromeCOVID-19

Interventions

Bronchoalveolar Lavage

Condition Hierarchy (Ancestors)

Respiratory Tract DiseasesLung DiseasesPneumonia, ViralPneumoniaRespiratory Tract InfectionsInfectionsVirus DiseasesCoronavirus InfectionsCoronaviridae InfectionsNidovirales InfectionsRNA Virus Infections

Intervention Hierarchy (Ancestors)

Therapeutic IrrigationInvestigative Techniques

Study Officials

  • Francesco Ricottilli, MD

    Intensive Care Unit - Erasme University Hospital

    PRINCIPAL INVESTIGATOR
  • Leda Nobile, MD

    Intensive Care Unit - Erasme University Hospital

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Francesco Ricottilli, MD

CONTACT

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Resident

Study Record Dates

First Submitted

August 3, 2020

First Posted

August 6, 2020

Study Start

September 1, 2020

Primary Completion

March 30, 2021

Study Completion

April 30, 2021

Last Updated

February 8, 2021

Record last verified: 2021-02

Locations